ORGANIZATION

2012 New Year’s Message: The Ultimate Winner of the Medical Policy Changes is the Patient

January 5, 2012
Ira Wolf, Japan Representative Pharmaceutical Research and Manufacturers of America The year 2011 was very challenging for the American pharmaceutical industry in Japan but also a very successful one. The events of March 11 had a profound effect on our…

To read the full story

ORGANIZATION

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Shinya Sato

More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…

By Philip Carrigan

A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…